Technical Analysis for HKMPF - Hikma Pharmaceutical

Grade Last Price % Change Price Change
grade A 24.4 6.09% 1.4000
HKMPF closed up 6.09 percent on Tuesday, February 18, 2020, on 4 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Flat
Historical HKMPF trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Strong but Oversold Other 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 6.09%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.09%
Narrow Range Bar Range Contraction 6.09%
BB Squeeze Ended Range Expansion 6.09%
Older signals for HKMPF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Health Pain Diabetes Pharmaceutical Industry In China Pain Management Pharmaceutical Companies Cardiovascular Products Lupin Limited Oncology Products Anti Infective Products Generic Injectable Products Hikma Pharmaceuticals

Is HKMPF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.25
52 Week Low 12.0
Average Volume 2,644
200-Day Moving Average 0.0000
50-Day Moving Average 23.4437
20-Day Moving Average 24.8796
10-Day Moving Average 24.3465
Average True Range 0.7104
ADX 11.88
+DI 50.1146
-DI 49.4519
Chandelier Exit (Long, 3 ATRs ) 24.5188
Chandelier Exit (Short, 3 ATRs ) 25.1312
Upper Bollinger Band 27.1597
Lower Bollinger Band 22.5995
Percent B (%b) 0.39
BandWidth 18.3291
MACD Line -0.0525
MACD Signal Line 0.2470
MACD Histogram -0.2995
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.4000
Resistance 3 (R3) 24.4000 24.4000 24.4000
Resistance 2 (R2) 24.4000 24.4000 24.4000 24.4000
Resistance 1 (R1) 24.4000 24.4000 24.4000 24.4000 24.4000
Pivot Point 24.4000 24.4000 24.4000 24.4000 24.4000
Support 1 (S1) 24.4000 24.4000 24.4000 24.4000 24.4000
Support 2 (S2) 24.4000 24.4000 24.4000 24.4000
Support 3 (S3) 24.4000 24.4000 24.4000
Support 4 (S4) 24.4000